GLIX5
Broad Range of Cancers
Proof-of-ConceptActive
Key Facts
About Hemispherian
Hemispherian is pioneering a novel epigenetic approach to cancer therapy by developing small molecule activators of the TET2 enzyme. This 'first-in-class' mechanism aims to selectively restore the depleted DNA modification 5-hydroxymethylcytosine in cancer cells, inducing cytotoxicity while sparing normal tissues. The company's lead asset, GLIX1, is advancing into clinical trials for glioblastoma through a partnership with BioLineRx, with a broader pipeline, including GLIX5, in earlier stages. Backed by public Norwegian and European support, Hemispherian is targeting high-unmet-need oncology indications with a potentially safer and more effective therapeutic strategy.
View full company profileTherapeutic Areas
Other Broad Range of Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Nanoencapsulation Platform Drug Candidates | Fulgent Genetics | Discovery/Preclinical |